Valneva (NASDAQ:VALN) Shares Down 11.2% – Time to Sell?

Valneva SE (NASDAQ:VALN) shares fell 11.2% on Friday . The company traded as low as $6.87 and last traded at $6.92. 79,836 shares traded hands during trading, an increase of 30% from the average session volume of 61,567 shares. The stock had previously closed at $7.79.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Valneva in a research note on Friday, January 31st.

Valneva Stock Down 14.4 %

The business’s 50-day simple moving average is $4.92 and its 200-day simple moving average is $5.66. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VALN. ABC Arbitrage SA purchased a new position in shares of Valneva during the 4th quarter valued at about $84,000. AlphaCentric Advisors LLC raised its position in Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after acquiring an additional 29,748 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after acquiring an additional 30,859 shares in the last quarter. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.